Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab and Mezigdomide for Relapsed/Refractory Multiple Myeloma
NCT07105059Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of teclistamab and mezigdomide in multiple myeloma (MM) (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Dose Limiting Toxicity at 1 year. Started Aug 2025; status: recruiting.
02
Drugs
teclistamabmezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07105059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07105059.